Swiss pricing and reimbursement planning checklist
MAH Switzerland | 2026-09-20

Use this worksheet to align regulatory, evidence, price and access decisions before selecting a specialist or filing strategy.

[ ] 1. Swissmedic status and target authorisation wording confirmed

[ ] 2. Requested SL population and limitation drafted

[ ] 3. EAE evidence mapped to each proposed claim

[ ] 4. Therapeutic comparators selected with rationale

[ ] 5. Nine-country price evidence availability assessed

[ ] 6. Dosing, pack and treatment-duration assumptions reconciled

[ ] 7. Base, restricted and delayed-listing scenarios modelled

[ ] 8. Cross-functional owners and authority-question process assigned


What is the product, Swissmedic status, intended reimbursed population, comparator set and target launch sequence?
https://mahswitzerland.com/en/blog/swiss-pricing-reimbursement/#article-review

FOPH: Prices of medicines in Switzerland, FAQs
https://www.bag.admin.ch/en/prices-of-medicines-in-switzerland-faqs
FOPH: Pharmaceuticals and medicinal products
https://www.bag.admin.ch/en/pharmaceuticals-and-medicinal-products
FOPH: Reimbursement for medicinal products in individual cases
https://www.bag.admin.ch/en/reimbursement-for-the-cost-of-medicinal-products-in-individual-cases
FOPH: Reference documents related to the Specialities List
https://www.bag.admin.ch/en/reference-documents-related-to-the-specialities-list